Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 68.42
NLNK's Cash to Debt is ranked higher than
76% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. NLNK: 68.42 )
NLNK' s 10-Year Cash to Debt Range
Min: 0.79   Max: No Debt
Current: 68.42

Equity to Asset 0.86
NLNK's Equity to Asset is ranked higher than
89% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NLNK: 0.86 )
NLNK' s 10-Year Equity to Asset Range
Min: -5.11   Max: 0.87
Current: 0.86

-5.11
0.87
F-Score: 4
Z-Score: 35.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3118.55
NLNK's Operating margin (%) is ranked higher than
52% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. NLNK: -3118.55 )
NLNK' s 10-Year Operating margin (%) Range
Min: -2849.13   Max: -801.39
Current: -3118.55

-2849.13
-801.39
Net-margin (%) -3128.42
NLNK's Net-margin (%) is ranked higher than
52% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. NLNK: -3128.42 )
NLNK' s 10-Year Net-margin (%) Range
Min: -2852.7   Max: -779.85
Current: -3128.42

-2852.7
-779.85
ROE (%) -47.62
NLNK's ROE (%) is ranked higher than
64% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. NLNK: -47.62 )
NLNK' s 10-Year ROE (%) Range
Min: -130.09   Max: -49.19
Current: -47.62

-130.09
-49.19
ROA (%) -40.83
NLNK's ROA (%) is ranked higher than
64% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. NLNK: -40.83 )
NLNK' s 10-Year ROA (%) Range
Min: -86.63   Max: -37.39
Current: -40.83

-86.63
-37.39
ROC (Joel Greenblatt) (%) -533.77
NLNK's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. NLNK: -533.77 )
NLNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -586.24   Max: -289.25
Current: -533.77

-586.24
-289.25
Revenue Growth (%) -59.90
NLNK's Revenue Growth (%) is ranked higher than
57% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NLNK: -59.90 )
NLNK' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -59.9
Current: -59.9

EBITDA Growth (%) -37.10
NLNK's EBITDA Growth (%) is ranked higher than
57% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. NLNK: -37.10 )
NLNK' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -37.1
Current: -37.1

EPS Growth (%) -36.70
NLNK's EPS Growth (%) is ranked higher than
60% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. NLNK: -36.70 )
NLNK' s 10-Year EPS Growth (%) Range
Min: 0   Max: -36.7
Current: -36.7

» NLNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NLNK Guru Trades in Q3 2013

Jean-Marie Eveillard 778,354 sh (+21.32%)
Jean-Marie Eveillard 1,078 sh (unchged)
» More
Q4 2013

NLNK Guru Trades in Q4 2013

Jim Simons 28,200 sh (New)
Jean-Marie Eveillard 905,154 sh (+16.29%)
Jean-Marie Eveillard 2,000 sh (unchged)
Jean-Marie Eveillard 5,965 sh (unchged)
» More
Q1 2014

NLNK Guru Trades in Q1 2014

Jean-Marie Eveillard 1,161,805 sh (+28.35%)
Jean-Marie Eveillard 3,285 sh (unchged)
Jean-Marie Eveillard 6,888 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

NLNK Guru Trades in Q2 2014

Jean-Marie Eveillard 1,306,970 sh (+12.49%)
Jean-Marie Eveillard 7,147 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Add 28.35%0.02%$21.38 - $50.4 $ 26.2-22%1161805
Jean-Marie Eveillard 2013-09-30 Add 21.32%0.01%$15.78 - $20.08 $ 26.247%778354
Jean-Marie Eveillard 2013-06-30 Add 95.04%0.02%$11.27 - $22.56 $ 26.267%641554
Jean-Marie Eveillard 2013-03-31 New Buy0.01%$11.4 - $12.7 $ 26.2117%328939
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.00
NLNK's P/B is ranked higher than
65% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. NLNK: 10.00 )
NLNK' s 10-Year P/B Range
Min: 3.6   Max: 21.14
Current: 10

3.6
21.14
P/S 625.00
NLNK's P/S is ranked higher than
63% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. NLNK: 625.00 )
NLNK' s 10-Year P/S Range
Min: 14   Max: 1162.5
Current: 625

14
1162.5
EV-to-EBIT -19.66
NLNK's EV-to-EBIT is ranked higher than
81% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NLNK: -19.66 )
NLNK' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -19.66

Current Ratio 20.28
NLNK's Current Ratio is ranked higher than
96% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. NLNK: 20.28 )
NLNK' s 10-Year Current Ratio Range
Min: 0.97   Max: 23.49
Current: 20.28

0.97
23.49
Quick Ratio 20.28
NLNK's Quick Ratio is ranked higher than
96% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. NLNK: 20.28 )
NLNK' s 10-Year Quick Ratio Range
Min: 0.97   Max: 23.49
Current: 20.28

0.97
23.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.20
NLNK's Price/Net Cash is ranked higher than
85% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. NLNK: 11.20 )
NLNK' s 10-Year Price/Net Cash Range
Min: 4.76   Max: 25.51
Current: 11.2

4.76
25.51
Price/Net Current Asset Value 11.10
NLNK's Price/Net Current Asset Value is ranked higher than
84% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. NLNK: 11.10 )
NLNK' s 10-Year Price/Net Current Asset Value Range
Min: 4.72   Max: 24.51
Current: 11.1

4.72
24.51
Price/Tangible Book 10.10
NLNK's Price/Tangible Book is ranked higher than
71% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. NLNK: 10.10 )
NLNK' s 10-Year Price/Tangible Book Range
Min: 3.93   Max: 14.71
Current: 10.1

3.93
14.71
Price/Median PS Value 3.60
NLNK's Price/Median PS Value is ranked higher than
68% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. NLNK: 3.60 )
NLNK' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 3.91
Current: 3.6

0.08
3.91

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4NX.Germany
NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The company is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small‑molecule immunotherapy product candidates intended to treat a range of oncology indications. Its lead product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically‑resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically‑resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator‑initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non‑patient specific) cells from previously established cell lines rather than cells derived from the patient. The company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The company is subject to federal, state, local and foreign regulation.
» More Articles for NLNK

Headlines

Articles On GuruFocus.com
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Our Partners
Momentum Stocks Showing Weakness Sep 15 2014 - BENZINGA

More From Other Websites
The Dire Need For A Rapid Diagnostic Ebola Test In West Africa Sep 18 2014
Containing Ebola Outbreak Requires American Leadership Sep 16 2014
Coverage initiated on NewLink Genetics by Mizuho Sep 12 2014
Gates Foundation Commits $50 Million To Ebola Containment Efforts Sep 10 2014
Experimental Ebola vaccine protects monkeys for 10 months Sep 07 2014
Experimental Ebola vaccine protects monkeys for 10 months Sep 07 2014
WHO urges use of blood-derived drugs against Ebola, backs vaccine trials Sep 05 2014
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events Sep 04 2014
FDA Gives NewLink Genetics Approval to Proceed to Phase 1 Clinical Studies of Their Ebola Vaccine Sep 04 2014
Experimental Ebola drug ZMapp cures 100 percent of lab monkeys Aug 29 2014
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events Aug 27 2014
NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session Aug 18 2014
NewLink Genetics: Ready to test Ebola vaccine Aug 14 2014
Why NewLink Genetics (NLNK) Stock Is Gaining Today Aug 14 2014
NEWLINK GENETICS CORP Financials Aug 12 2014
The Red-Hot Ebola Drug Stock Tekmira Is Down 20% Aug 12 2014
Why A Short Covering Rally Might Come for NewLink Genetics (NLNK) Stock Aug 07 2014
Cablevision's subscriber losses mount; shares down Aug 05 2014
Higher prices help Cablevision offset subscriber loss Aug 05 2014
NEWLINK GENETICS CORP Files SEC form 8-K, Other Events Aug 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK